Forum Topic News
  • Conversation: Clovis’ PARP inhibitor Rubraca under EU review in maintenance setting

    • July 9, 2018 12:58 PM BST
    • Clovis’ PARP inhibitor Rubraca under EU review in maintenance setting

      European regulators have agreed to review Clovis’ application to expand the use of its PARP inhibitor Rubraca in the region.
      The company is seeking permission to market Rubraca (rucaparib) for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum based chemotherapy.
      Read more: http://www.pharmatimes.com/news/clovis_parp_inhibitor_rubraca_under_eu_review_in_maintenance_setting_1243566

Add Reputation

Do you want to add reputation for this member by this post?

or cancel